Compare RMT & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMT | INBX |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.2M | 430.2M |
| IPO Year | N/A | 2020 |
| Metric | RMT | INBX |
|---|---|---|
| Price | $10.60 | $80.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 111.5K | ★ 236.0K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | N/A | ★ $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | $230.77 |
| P/E Ratio | $6.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.67 | $10.81 |
| 52 Week High | $9.51 | $94.47 |
| Indicator | RMT | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 51.68 |
| Support Level | $10.53 | $79.00 |
| Resistance Level | $10.94 | $94.47 |
| Average True Range (ATR) | 0.18 | 6.11 |
| MACD | 0.06 | -1.56 |
| Stochastic Oscillator | 69.03 | 12.77 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector including auto components, automobiles, diversified consumer services, hotels, restaurants and leisure, household durables, internet and catalog retail, leisure products, media, multiline retail, textiles, apparels, and luxury goods, Consumer staples sector including beverages, food, and staples retailing, food products, and personal products, Energy sector including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors including healthcare, financials, industrials, IT, telecommunications, and materials.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.